Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Degarelix acetate 88.2 mg eqv degarelix
FERRING PHARMACEUTICALS PRIVATE LIMITED
L02BX02
80 mg
INJECTION, POWDER, FOR SOLUTION
Degarelix acetate 88.2 mg eqv degarelix 80 mg
SUBCUTANEOUS
Prescription Only
Rentschler Biopharma SE (Powder)
ACTIVE
2013-05-13
xxxxxxxxxx FIRMAGON ® 80mg Powder and solvent for solution for injection QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 80 mg degarelix (as acetate). After reconstitution, each ml of solution contains 20 mg of degarelix. List of excipients: Powder: Mannitol (E421). Solvent: Water for injections. PHARMACEUTICAL FORM Powder and solvent for solution for injection Powder: White to off-white powder. Solvent: Clear, colourless solution. THERAPEUTIC INDICATIONS FIRMAGON ® is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer. POSOLOGY AND METHOD OF ADMINISTRATION Posology Starting dose Maintenance dose – monthly administration 240 mg administered as two consecutive subcutaneous injections of 120 mg each 80 mg administered as one subcutaneous injection The first maintenance dose should be given one month after the starting dose. The therapeutic effect of degarelix should be monitored by clinical parameters and prostate specific antigen (PSA) serum levels. Clinical studies have shown that testosterone (T) suppression occurs immediately after administration of the starting dose with 96% of the patients having serum testosterone levels corresponding to medical castration (T≤0.5 ng/ml) after three days and 100% after one month. Long term treatment with the maintenance dose up to 1 year shows that 97% of the patients have sustained suppressed testosterone levels (T≤0.5 ng/ml). In case the patient's clinical response appears to be sub-optimal, it should be confirmed that serum testosterone levels are remaining sufficiently suppressed. Since degarelix does not induce a testosterone surge it is not necessary to add an anti-androgen as surge protection at initiation of therapy. Method of administration FIRMAGON ® must be reconstituted prior to administration. For instructions on reconstitution and administration, please see section Instructions For Use. FIRMAGON ® is for subcutaneous use ONLY, not to be administe Read the complete document
FIRMAGON ® 80MG AND 120MG Powder and solvent for solution for injection QUALITATIVE AND QUANTITATIVE COMPOSITION FIRMAGON 80 mg powder and solvent for solution for injection Each vial contains 80 mg degarelix (as acetate). After reconstitution, each ml of solution contains 20 mg of degarelix. FIRMAGON 120 mg powder and solvent for solution for injection Each vial contains 120 mg degarelix (as acetate). After reconstitution, each ml of solution contains 40 mg of degarelix. List of excipients: Powder: Mannitol (E421). Solvent: Water for injections. PHARMACEUTICAL FORM Powder and solvent for solution for injection Powder: white to off-white powder. Solvent: clear, colourless solution. THERAPEUTIC INDICATIONS FIRMAGON ® is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer. POSOLOGY AND METHOD OF ADMINISTRATION Posology STARTING DOSE MAINTENANCE DOSE – MONTHLY ADMINISTRATION 240 mg administered as two consecutive subcutaneous injections of 120 mg each 80 mg administered as one subcutaneous injection The first maintenance dose should be given one month after the starting dose. The therapeutic effect of degarelix should be monitored by clinical parameters and prostate specific antigen (PSA) serum levels. Clinical studies have shown that testosterone (T) suppression occurs immediately after administration of the starting dose with 96% of the patients having serum testosterone levels corresponding to medical castration (T≤0.5 ng/ml) after three days and 100% after one month. Long term treatment with the maintenance dose up to 1 year shows that 97% of the patients have sustained suppressed testosterone levels (T≤0.5 ng/ml). In case the patient's clinical response appears to be sub-optimal, it should be confirmed that serum testosterone levels are remaining sufficiently suppressed. Since degarelix does not induce a testosterone surge it is not necessary to add an anti-androgen as surge protection at initiation of therapy Read the complete document